Sat Kartar Life in FY26: Profits Up Sharply as the Company Adds a Hospital Engine

Sat Kartar Life Limited, formerly Sat Kartar Shopping Limited, ended FY26 with a clear message to investors: the company wants to remain a products-led Ayurveda business, but it is now building an integrated healthcare platform around hospitals, therapies, and an in-house pharmacy model.

The financial performance in FY26 was strong on paper. Consolidated revenue from operations rose to INR 200.70 crore in FY26 from INR 162.92 crore in FY25, a 23.19% year-on-year increase. Profitability expanded faster than revenue. EBITDA climbed 73.51% to INR 24.69 crore, while PAT from operations grew 74.31% to INR 17.10 crore. Margins improved too, with EBITDA margin at 12.30% and PAT margin at 8.52%.

The second half carried better momentum. H2FY26 revenue came in at INR 110.62 crore versus INR 87.13 crore in H2FY25. H2FY26 PAT from operations was INR 9.80 crore versus INR 5.99 crore in the prior-year period, and EBITDA margin improved to 13.44%.

The products business remains the base

The company positions itself as a modern Ayurveda healthcare company with a D2C-led sales model across its website, e-commerce platforms, TV, and digital marketing channels. It also highlights operational infrastructure built around multilingual sales and support, with more than 2,500 employees and communication support across multiple Indian languages.

A key disclosure in the presentation is the revenue concentration across therapeutic categories. It states that sexual wellness, diabetes, piles care, de-addictions, and bone and joints contribute 80% of revenue. The remaining 20% is contributed by categories such as PCOS/PCOD, respiratory support, hair care, liver care, infertility support, mind care, immune support, lungs care, and personal care.

This mix matters because the next phase of growth, as described by management, is expected to be driven by higher conversion, deeper penetration into smaller contributing pockets of India, and ticket-size expansion. On the earnings call, management stated that the average ticket size moved from around 3,100 at the time the company became public to above 3,250, with an internal target to cross 3,500.

Financial summary

The hospital launch is the turning point in strategy

The central strategic change in H2FY26 was the commissioning of Sat Kartar Sanjeevan, an Ayurveda specialty hospital in Delhi. The presentation describes it as a 30-bed facility built across 13,500 square feet, with 4 OPDs and therapy infrastructure including consultation rooms, therapy rooms, recovery rooms, and a procedure room. The company disclosed an investment of about INR 2 crore, funded via internal accruals and IPO funds, and stated that the hospital became operational with effect from March 5, 2026.

The hospital model is presented as capital efficient. The presentation cites setup cost of INR 7 to 8 lakh per bed, and positions the rollout as asset-light through leased facilities. It also claims average revenue productivity of INR 10,000 per bed per day and emphasizes an integrated pharmacy opportunity through doctor-prescribed medicines manufactured in-house.

However, in the earnings call, management acknowledged that the initial utilization is low. It said the hospital had not crossed 10% occupancy in the first 40 days, and that key operational enablers such as insurance and government empanelment were still underway, expected by end of May 2026. Management also shared that break-even for the hospital is around INR 1 lakh revenue per day.

The company’s roadmap is aggressive. The investor deck targets expansion from 30 beds in FY26 to 300 beds in FY27E and 1,000 beds in FY28E. It also states that hospitals are expected to contribute INR 100+ crore by FY28.

On execution, management provided process details in the Q&A. It indicated future facilities may be in the 50 to 100 bed range, with four facilities potentially required to reach 300 beds. It said that after finalizing locations, interiors and licensing could take about 6 to 8 months. At the time of the call, management stated it had identified focus areas such as Tamil Nadu and Visakhapatnam but had not finalized districts or properties.

Jeena Sikho partnership and a funded expansion plan

In April 2026, the company entered a 3-year strategic MoU with Jeena Sikho Lifecare Limited. The presentation frames it as a collaboration to build a technology-enabled Ayurveda healthcare ecosystem, combining digital patient engagement with institutional treatment infrastructure.

Management’s call commentary adds more operating logic. It said Jeena Sikho has around 2,800 beds in North India and that Sat Kartar can route interested patients to Jeena Sikho’s facilities and earn a revenue share. In South India, Sat Kartar aims to open hospitals under its own balance sheet, while using Jeena Sikho’s clinical know-how and processes, with Jeena Sikho charging a management fee. Management clarified the agreement is non-exclusive and that branding is still being worked out, with a possible co-powered approach.

To support this broader platform buildout, Sat Kartar approved a preferential issue raising INR 48.58 crore at INR 172 per equity share or warrant. The presentation states participation by 15 investors led by Lighthouse Canton, and discloses the structure as 50,400 equity shares and 27.74 lakh convertible warrants.

The company also consolidated ownership of Plantomed Nutraceuticals by buying an additional 24% stake for INR 1.21 crore, making it a wholly owned subsidiary. Plantomed is positioned as diabetes-focused, low ticket size, and high repeat.

On the concall, management said there are currently three subsidiaries and a fourth planned US company. It also stated that as of March 2026, revenue from subsidiaries was INR 1.2 crore, and guided that subsidiary revenue could be INR 25 to 30 crore in FY27.

What management guided for FY27 and FY28

The company gave explicit revenue direction. Management stated targets of INR 300 crore in FY27 and INR 500+ crore in FY28, and it also clarified that this guidance is for the products business. Hospital revenue is described as incremental upside.

On margins, management stated that moving from INR 160 crore to INR 200 crore revenue improved PAT margin from about 6% to 8.5%, and that scaling from INR 200 crore to INR 300 crore could lift PAT margins toward 11 to 12% for the products business. For the hospital business, management stated that at 60% occupancy, hospital margins could be 30 to 35%.

One recurring constraint is advertising intensity. Management stated that advertising remains around 40% of revenue and is unlikely to reduce materially for a product-only model. The implied margin expansion plan is therefore driven by scale, operating leverage, and the hospital engine.

Key takeaways

Sat Kartar Life’s FY26 numbers show a clear step-up in profitability, with EBITDA and PAT growth far outpacing revenue growth. The bigger strategic move is the entry into institutional Ayurveda healthcare through a 30-bed hospital in Delhi, paired with an aggressive expansion roadmap and a strategic MoU with Jeena Sikho.

The next 12 to 18 months will likely be judged on execution evidence: higher utilization at the Delhi hospital post empanelments, confirmed locations and licensing progress for new hospitals, and delivery against the INR 300 crore and INR 500+ crore product revenue targets. The company has raised growth capital and outlined unit economics, but early hospital occupancy and working-capital related cash conversion remain watch points.